Portage Biotech Inc expected to post a loss of 29 cents a share - Earnings Preview

Alpha Compute

18/11/2022 14:15

* Portage Biotech Inc  PRTG.OQ   PRTG.O  is expected to show
no
change in quarterly revenue when it reports  results on November
21 (estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Portage Biotech Inc
is
for a loss of 29 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Portage
Biotech
Inc is $26​, above​ its last closing price of $5.72. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.27       -0.30      -0.13     Beat    56.2
 Mar. 31 2022              -0.28      -0.56     Missed  -102.4
 Dec. 31 2021  -0.27       -0.27      -0.26     Beat    4.9​
 Sep. 30 2021  -0.26       -0.25      -0.22     Beat    13.2
 ​​Jun.        -0.21       -0.21      -0.25     Missed  -19
 30 2021                                                
                                                        ​
 This summary was machine generated November 18 at 14:15 GMT. 
All figures in US dollars  unless otherwise stated